Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury

Eligibility Criteria

• * Admitted to an ICU requiring CKRT:
• 1. Must have AKI stage 2 or greater at the time of CKRT initiation.
• 2. Must have been on CKRT for at least 12 hours but no greater than 48 hours at the time of enrollment.
• * At least 18 years of age but not older than 80 at the time of enrollment.
• * One additional life-threatening organ dysfunction present.
• * Acceptable vascular access for CKRT to include adequate lumen size and length of catheters.
• * Initial (non-binding) commitment to maintaining current level of care for at least 96 hours.
• * C-Reactive Protein \>3.5 mg/dl.
• * Not expected to survive next 24 hours.
• * Anticipated transition to comfort measures or hospice in next 4 days.
• * Terminal condition whereby the patient is not expected to survive 28 days or any condition in which therapy is regarded as futile by the PI.
• * Advanced malignancy which is actively being treated or may be treated with palliative chemotherapy or radiation.
• * ICU hospitalization \> 14 days during this hospital admission (to include days spent at ICU of an outside hospital) at the time of screening.
• * Active COVID-19 infection with a primary admission diagnosis of COVID-19.
• * Chronic use of ventricular assist devices.
• * ESRD requiring chronic kidney replacement therapy.
• * History of CKD (greater than Stage 3).
• * AKI stage 0 or stage 1 at the time of CKRT initiation.
• * Non-ATN AKI diagnosis. We intend on relying on local nephrology subspecialty expertise to reasonably exclude non-ATN diagnoses based on clinical suspicions combined with prespecified objective criteria. If there is a reasonable suspicion that the subject has non-ATN AKI based on this, they will be excluded from the trial.
• * Acute coronary syndromes, acute stroke, or acute major vascular compromise requiring medical or surgical interventions within 48 hours of randomization.
• * Active hemorrhage requiring blood transfusions at the time of screening.
• * Acute on Chronic Liver Failure.
• * Suspicion of hepato-renal syndrome.
• * Presence of any solid organ transplant at any time prior to admission.
• * Severe burns with a modified Baux score \> 100 (%TBSA+Age+17 for Inhalation Injury).
• * Bone marrow transplant within the last year.
• * Chronic immunosuppression with an average of \>20 mg/day of prednisone or other steroid sparing immunosuppressants for the past 30 days prior to hospital admission.
• * Individuals who have a history of primary or secondary immune disorders including, but not limited to, HIV or AIDS.
• * Dry weight of \>150kg.
• * Platelet count \<15,000/mm3.
• * Patient is a prisoner or member of a vulnerable population.
• * Patient is pregnant or breast feeding.
• * Concurrent enrollment in another interventional clinical trial for an investigational drug or device.
• * Need for plasmapheresis.